SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, reported a new Phase IIb trial of SCI-110, a proprietary THC-based medication for Tourette Syndrome (TS) treatment.
Global Collaboration for TS Advancements
Spanning across renowned institutions such as Yale University, Tel Aviv Sourasky Medical Center and Hannover Medical School, the trial operates under the regulations of the Food and Drug Administration, BfArM and Israeli Ministry of Health.
Addressing a significant gap in TS management, SCI-110 combines FDA-approved synthetic THC (Dronabinol) with …